$1.04
2.80% yesterday
Nasdaq, Dec 24, 07:46 pm CET
ISIN
US44148G1058
Symbol
HOTH

Hoth Therapeutics, Inc. Stock price

$1.04
-0.10 8.77% 1M
-0.24 18.75% 6M
+0.29 39.02% YTD
+0.25 32.15% 1Y
-2.22 68.10% 3Y
-40.46 97.49% 5Y
-212.21 99.51% 10Y
-212.21 99.51% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
-0.03 2.80%
ISIN
US44148G1058
Symbol
HOTH
Industry

Key metrics

Basic
Market capitalization
$16.1m
Enterprise Value
$8.3m
Net debt
positive
Cash
$7.9m
Shares outstanding
15.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
2.0
Financial Health
Equity Ratio
89.2%
Return on Equity
-119.0%
ROCE
-147.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | -
EBIT
$-12.1m | $-13.1m
Net Income
$-12.2m | $-8.0m
Free Cash Flow
$-10.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
-61.2% | -59.5%
Net Income
-62.1% | 2.1%
Free Cash Flow
-24.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.9
FCF per Share
$-0.7
Short interest
3.9%
Employees
3
Rev per Employee
$0.0
Show more

Is Hoth Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Hoth Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Hoth Therapeutics, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Hoth Therapeutics, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Hoth Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.19 6.19
21% 21%
-
- Research and Development Expense 5.95 5.95
110% 110%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -12 -12
61% 61%
-
Net Profit -12 -12
62% 62%
-

In millions USD.

Don't miss a Thing! We will send you all news about Hoth Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Hoth Therapeutics, Inc. Stock News

Neutral
PRNewsWire
22 days ago
NEW YORK , Dec. 3, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today issued a comprehensive update on its therapeutic pipeline. The Company detailed meaningful progress across HT-001, HT-KIT, HT-ALZ, and its newly launched GDNF-based metabolic program, while continuing to strengthen its global intellectual-property por...
Neutral
PRNewsWire
24 days ago
NobleCon is the preeminent showcase of small and microcap companies NEW YORK , Dec. 1, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to present at the Noble Capital Markets 21st Annual Emerging Growth Equity Conference in Boca Raton, FL. To learn more about NobleCon ...
Neutral
PRNewsWire
about one month ago
NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics today announced that it has been officially accepted into the NVIDIA Connect Program, a global initiative supporting innovative software and technology companies working with advanced computing and AI platforms. Acceptance in...
More Hoth Therapeutics, Inc. News

Company Profile

Hoth Therapeutics, Inc. is a development stage biopharmaceutical company, which engages in the provision and development of therapeutic platform. The company focuses on the patients suffering from conditions such as atopic dermatitis, also known as eczema. It offers BioLexa Platform, a proprietary, patented, drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern in May 2017 and is headquartered in New York, NY.

Head office United States
CEO Robbie Knie
Employees 3
Founded 2017
Website hoththerapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today